×
About 98,638 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  32,947 results

Effects of metformin and statins on outcomes in men with castration-resistant metastati...
https://doi.org/10.1016/j.ejca.2022.03.042
European Journal of Cancer (Oxford, England : 1990); Wilson BE, Armstrong AJ et. al.

May 15th, 2022 - The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. To determine whether metformin or statins ± abir...

Transcription associated cyclin-dependent kinases as therapeutic targets for prostate c...
https://doi.org/10.1038/s41388-022-02347-1 10.1080/21541264.2018.1553483 10.4161/trns.25146 10.1016/j.cell.2016.12.013 10.1210/er.2002-0032 10.1021/cr400071f 10.1101/gad.200303.112 10.1093/emboj/19.1.25 10.7554/eLife.44771 10.1038/nrm.2017.115 10.1016/j.molcel.2014.03.024 10.1016/j.bbagrm.2012.08.010 10.4161/rna.21166 10.1016/j.molcel.2015.06.032 10.1016/j.molcel.2009.09.018 10.1074/jbc.RA117.001347 10.1038/nsmb.2399 10.1074/jbc.270.21.12335 10.1016/j.celrep.2017.07.021 10.1016/j.molcel.2007.11.010 10.1101/gad.341545.120 10.1016/j.molcel.2008.04.024 10.1038/s41467-019-10745-5 10.1101/gad.14.3.349 10.1080/21541264.2017.1344346 10.1016/S1097-2765(03)00388-5 10.1016/j.molcel.2005.06.029 10.1038/s41586-018-0442-2 10.1016/j.molcel.2005.11.024 10.1016/S1097-2765(03)00492-1 10.1126/science.1206034 10.1101/gad.269589.115 10.1038/embor.2009.108 10.1038/nsmb.3000 10.1126/sciadv.abd4484 10.4172/jpb.S2-004 10.1038/s41588-020-0635-0 10.1038/nature14904 10.1016/j.celrep.2016.03.030 10.1080/21541264.2018.1535211 10.1038/s41467-019-09703-y 10.1038/s41586-018-0758-y 10.1038/s41589-021-00765-y 10.1093/nar/gkx187 10.1128/MCB.01426-14 10.1038/sj.onc.1204295 10.1073/pnas.1306814110 10.1074/jbc.M708188200 10.1038/s41594-020-0406-8 10.1126/science.1117679 10.1038/sj.bjc.6604054 10.1038/ng.3419 10.1016/j.ejca.2014.04.004 10.1038/emboj.2010.337 10.1074/jbc.M802392200 10.1158/2159-8290.CD-19-0189 10.1210/me.2010-0238 10.1128/MCB.01753-06 10.1016/j.chembiol.2020.10.001 10.18632/oncotarget.24414 10.1038/s41419-021-04027-6 10.1186/gb4184 10.1038/nrd4504 10.1158/0008-5472.CAN-09-0301 10.1158/1535-7163.MCT-16-0847 10.1038/nature13393 10.1038/nchembio.2166 10.1016/j.chembiol.2019.02.012 10.1016/j.ccell.2019.11.003 10.1021/acs.jmedchem.1c01171 10.1158/0008-5472.CAN-19-0119 10.1016/S0959-8049(20)31201-6 10.1517/13543784.2013.789859 10.1002/cmdc.201700447 10.1182/blood-2016-09-741983 10.1182/blood-2018-99-117257 10.1200/JCO.2018.36.15_suppl.2507 10.1200/JCO.2021.39.15_suppl.7538 10.1158/1078-0432.CCR-19-1853 10.1021/acs.jmedchem.0c01754 10.1016/j.ejmech.2021.113481 10.1016/j.ccell.2019.09.004 10.1016/j.cell.2015.10.025 10.7554/eLife.20722 10.3390/cells8111413 10.18632/oncotarget.16810 10.1016/j.celrep.2017.09.056 10.1016/j.annonc.2021.08.291 10.1016/j.cell.2018.09.051 10.1186/s12943-020-01301-7 10.3390/cells9030638 10.1186/s13058-019-1161-9 10.1158/2159-8290.CD-17-0461 10.1038/s41388-019-0953-9 10.1038/s41375-019-0652-0 10.1038/s41392-020-0112-3 10.1158/1535-7163.MCT-17-0078 10.1038/s41588-018-0191-z 10.1182/bloodadvances.2019000586 10.1016/j.ccell.2017.03.011 10.1038/s41698-020-00137-0 10.1016/j.cell.2018.07.045
Oncogene Constantin TA, Greenland KK et. al.

May 15th, 2022 - Transcriptional deregulation has emerged as a hallmark of several cancer types. In metastatic castration-resistant prostate cancer, a stage in which systemic androgen deprivation therapies fail to show clinical benefit, transcriptional addiction t...

High intratumoral plasma cells content in primary prostate cancer defines a subset of t...
https://doi.org/10.1038/s41391-022-00547-0 10.1056/NEJMoa1001294 10.1200/JCO.19.01638 10.3389/fonc.2019.00884 10.1126/scitranslmed.aaz3577 10.1038/nm.4308 10.1016/j.juro.2006.10.040 10.1038/s41577-019-0257-x 10.1038/s41586-019-1922-8 10.1038/s41586-019-1914-8 10.1038/s41586-019-1906-8 10.1038/s41467-021-21245-w 10.1016/j.eururo.2015.05.042 10.1038/s41379-018-0083-x 10.1016/j.juro.2013.06.017 10.1073/pnas.1902651116 10.1038/ncomms3612 10.1186/s12859-018-2069-6 10.1038/s41598-017-17204-5 10.1172/JCI91190 10.1126/science.aar3593 10.1158/1078-0432.CCR-19-1587 10.1016/S1470-2045(16)30491-0 10.1200/JCO.2016.70.2811 10.1016/j.celrep.2016.12.019 10.1038/nature08712 10.1038/msb.2010.31 10.1038/ng.3593 10.1016/j.ccr.2014.03.017 10.1038/nature14395 10.1016/j.eururo.2021.01.017 10.1038/88756 10.1016/j.ccell.2016.04.012 10.1001/jamaoncol.2021.1463 10.1016/j.annonc.2021.06.003 10.1371/journal.pone.0098187 10.1016/j.imlet.2016.04.007 10.4049/jimmunol.165.5.2474 10.1038/nm.2958 10.1016/j.it.2020.04.007 10.4049/jimmunol.181.3.1644 10.6004/jnccn.2021.0008 10.1038/srep36772 10.2353/ajpath.2009.080776
Prostate Cancer and Prostatic Diseases; Weiner AB, Yu CY et. al.

May 15th, 2022 - Data on advanced prostate cancer (PCa) suggest more prior systemic therapies might reduce tumor immune responsiveness. In treatment-naïve primary PCa, recent work correlated intratumoral plasma cell content with enhanced tumor immune-responsivenes...

Adding metabolic agents to prostate cancer therapy: Every rose has its thorn.
https://doi.org/10.1016/j.ejca.2021.04.048
European Journal of Cancer (Oxford, England : 1990); Buck SAJ, Mathijssen RHJ et. al.

May 15th, 2022 - Adding metabolic agents to prostate cancer therapy: Every rose has its thorn.|2022|Buck SAJ,Mathijssen RHJ,de Wit R,|

Mediterranean Style Dietary Pattern with High Intensity Interval Training in Men with P...
https://doi.org/10.3390/ijerph19095709
International Journal of Environmental Research and Publi... Baguley BJ, Adlard K et. al.

May 15th, 2022 - Background: Androgen deprivation therapy (ADT) in prostate cancer has been shown to deteriorate body composition (reduced lean mass and increased body and fat mass) and increase the risk of cardiovascular morbidity. The Mediterranean style dietary...

see more →

Guidelines  77 results

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Endorsed by SUO
https://www.auanet.org/guidelines/guidelines/clinically-localized-prostate-cancer-aua/astro-guideline-2022
Journal of Urology; Eastham JA, Auffenberg GB et. al.

May 10th, 2022 - The recommendations discussed herein for the management of clinically localized prostate cancer provide a framework stratified by risk to facilitate care decisions and guide clinicians in the implementation of selected management options.

GEC-ESTRO ACROP prostate brachytherapy guidelines.
https://doi.org/10.1016/j.radonc.2021.12.047
Radiotherapy and Oncology : Journal of the European Socie... Henry A, Pieters BR et. al.

Jan 10th, 2022 - This is an evidence-based guideline for prostate brachytherapy. Throughout levels of evidence quoted are those from the Oxford Centre for Evidence based Medicine (https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-ba...

The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate...
https://doi.org/10.1016/j.euf.2021.09.008
European Urology Focus; Beyer K, MacLennan SJ et. al.

Oct 5th, 2021 - Patients are the stewards of their own care and hence their voice is important when designing and implementing research. Patients should be involved not only as participants in research that impacts their care, as the recipients of that care and a...

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
https://doi.org/10.6004/jnccn.2021.0008
Journal of the National Comprehensive Cancer Network : JN... Schaeffer E, Srinivas S et. al.

Feb 6th, 2021 - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of r...

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: A...
https://doi.org/10.1200/JCO.20.03256
Journal of Clinical Oncology : Official Journal of the Am... Virgo KS, Rumble RB et. al.

Jan 27th, 2021 - Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. The Expert Panel based recommendations on a systematic literature review. Recommendations were approved by the E...

see more →

Drugs  211 results see all →

Clinicaltrials.gov  1,640 results

Radiation Therapy in Treating Patients With Stage II Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT00331773

May 13th, 2022 - OBJECTIVES: Primary Compare the disease-free survival (DFS) of patients with favorable-risk stage II prostate cancer treated with hypofractionated vs conventionally fractionated three-dimensional conformal radiotherapy (3D-CRT) or intensity-modula...

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
https://clinicaltrials.gov/ct2/show/NCT03493945

May 13th, 2022 - Background: PD-1/PD-L1 signaling appears to be a major inhibitor of activated T cell anti-tumor immune responses. The rapid, deep and durable responses seen in various malignancies with PD-1/PD-L1 targeted agents demonstrate that blockade of this ...

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT04663997

May 13th, 2022 - The standard or usual treatment for this disease is a chemotherapy drug called docetaxel, given by intravenous every 3 weeks, for up to 12 treatments. 177Lu-PSMA-617 is a new type of therapy for prostate cancer. Laboratory tests show that it may h...

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
https://clinicaltrials.gov/ct2/show/NCT04086485

May 13th, 2022 - Background: Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. While the tr...

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03860987

May 13th, 2022 - Background: Most men diagnosed with prostate cancer will present with intermediate or high-risk disease, and many develop castrate resistant prostate cancer (CRPC) as curative strategies are often unsuccessful Treatment options typically involve r...

see more →

News  4,507 results

Most Men With Low-Risk Prostate Tumors Now Forgoing Treatment
https://www.medscape.com/viewarticle/974009

May 15th, 2022 - The number of men with prostate cancer who opted for active surveillance (AS)   doubled nationally between 2014 and 2021, according to experts who say the dramatic increase reflects a growing understanding among both researchers and patients that ...

Nearly 234,000 Cancer Cases Predicted in Canada This Year
https://www.medscape.com/viewarticle/973931

May 13th, 2022 - About 233,900 new cancer cases and 85,100 cancer deaths are predicted to occur in Canada in 2022, according to new research. The most commonly diagnosed cancer overall will be lung cancer, followed by breast cancer for women and prostate cancer fo...

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Endorsed by SUO
https://www.auanet.org/guidelines/guidelines/clinically-localized-prostate-cancer-aua/astro-guideline-2022
Journal of Urology; Eastham JA, Auffenberg GB et. al.

May 10th, 2022 - The recommendations discussed herein for the management of clinically localized prostate cancer provide a framework stratified by risk to facilitate care decisions and guide clinicians in the implementation of selected management options.

New Guideline Gives Active Surveillance a Boost
https://www.medscape.com/viewarticle/973714

May 10th, 2022 - Two major medical groups strengthened their recommendations for active surveillance (AS) for patients with low-risk prostate cancer and for the first time recommended the approach for some patients with favorable intermediate-risk prostate cancer....

DNA Alterations and Selection of PARP Inhibitors in mCRPC
https://www.onclive.com/view/dna-alterations-and-selection-of-parp-inhibitors-in-mcrpc

May 6th, 2022 - Transcript: Alicia Morgans, MD, MPH: I want to pick up on one of the threads that you dropped related to differential responsiveness of particular alterations in patients to specific PARP inhibitors. I think this is a question that remains one of...

see more →

Patient Education  73 results see all →